Loic Vincent (Takeda)

March 9, 2021 07:11 AM ESTUpdated March 12, 04:57 AM

Takeda goes all in with build-to-buy play, picking up Maverick and its clinic-ready T cell engagers for $525M

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Regeneron makes $80M obesity deal with Hansoh

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...